Vigonvita Life Sciences Co., Ltd.
蘇州旺山旺水生物醫藥股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2630)

(1) PROPOSED ABOLITION OF THE SUPERVISORY COMMITTEE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND ITS APPENDICES;
(2) ELECTION OF THE NEW SESSION OF THE BOARD; AND
(3) POSTPONEMENT OF THE ANNUAL GENERAL MEETING

I. PROPOSED ABOLITION OF THE SUPERVISORY COMMITTEE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND ITS APPENDICES

The Board (the "**Board**") of Directors (the "**Director(s)**") of Vigonvita Life Sciences Co., Ltd. (the "**Company**") hereby announces that, in order to comply with the newly amended Company Law of the People's Republic of China (the "**Company Law**") and further optimize the Company's corporate governance structure, in accordance with the Company Law, the Guidelines for the Articles of Association of Listed Companies and other relevant laws, regulations, rules and normative documents, the Company intends to abolish its supervisory committee (the "**Supervisory Committee**") and repeal the Rules of Procedure of the Supervisory Committee of Vigonvita Life Sciences Co., Ltd. The powers and duties of the Supervisory Committee shall be exercised by the audit committee of the Board and provisions relating to the Supervisory Committee and supervisors (the "**Supervisor(s)**") set forth in the Company's various relevant rules and regulations shall no longer apply.

In addition, the Company intends to amend the Articles of Association of Vigonvita Life Sciences Co., Ltd. (the "**Articles of Association**") (the "**Amendments**"). In view of the proposed amendments to the Articles of Association, the Board also proposes to amend the Rules of Procedure for Shareholders' Meetings of Vigonvita Life Sciences Co., Ltd. (the "**Rules of Procedure for Shareholders' Meetings**") and the Rules of Procedure for Board Meetings of Vigonvita Life Sciences Co., Ltd. (the "**Rules of Procedure for Board Meetings**") to bring them in line with the Amendments.

Proposed abolition of the Supervisory Committee and amendments to the Articles of Association and the adoption of the amended Articles of Association are subject to consideration and approval by the shareholders of the Company (the "**Shareholders**") by way of a special resolution at the forthcoming annual general meeting of the Company (the "**Annual General Meeting**"). Proposed amendments to the Rules of Procedure for Shareholders' Meetings and the Rules of Procedure for Board Meetings are subject to consideration and approval by the Shareholders by way of an ordinary resolution at the Annual General Meeting.

Upon the amended Articles of Association coming into effect, the current members of the Supervisory Committee shall cease to hold their positions as Supervisors and perform their duties on the Supervisory Committee. The existing Articles of Association remain effective prior to the consideration and approval of the relevant resolution at the Annual General Meeting, and the members of the first session of the Supervisory Committee shall continue to fulfill their respective obligations and responsibilities in accordance with the relevant laws and regulations and the Articles of Association.

II. ELECTION OF THE NEW SESSION OF THE BOARD

In view of the expiry of the term of office of the first session of the Board on March 26, 2026, and in accordance with the provisions of the Articles of Association, the Company intends to hold elections for the new session of the Board. The Board hereby nominates the following candidates for the directors representing the Shareholders for the second session of the Board:

(1) Candidates for executive Directors: Dr. Tian Guanghui and Dr. Hu Tianwen;

(2) Candidate for non-executive Director: Mr. Liu Haoxuan;

(3) Candidates for independent non-executive Directors: Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi.

The term of office for members of the second session of the Board shall be three years commencing immediately upon approval at the Annual General Meeting and the formation thereof, and the Directors may be re-elected for consecutive terms. The biographical details and disclosable information regarding the aforementioned candidates for the Directors are set out in the appendices to this announcement.

The above-mentioned candidates for independent non-executive Directors have confirmed that they satisfy the criteria for independence set out in Rules 3.13(1) to (8) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), and they had/have no financial or other interests in the business of the Company or its subsidiaries, either in the past or at present; they are not connected to any core connected persons (as defined in the Listing Rules) of the Company; and there are no other factors that might affect their independence at the time of their appointment.

Save as disclosed in this announcement, as at the date of this announcement, each of the candidates for the members of the second session of the Board have confirmed that: (1) they have not held any directorship in any other public companies, the securities of which are listed on any securities markets in Hong Kong or overseas during the last three years, nor have they held any other position in the Company or any of its subsidiaries; (2) they have not held any other major appointments and professional qualifications; (3) they have no relationship with any directors, supervisors, senior management, controlling shareholders or substantial shareholders of the Company; (4) they do not hold any interest in the shares of the Company (as defined in Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)); and (5) there is no information required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules, nor are there any matters that require the attention of the Shareholders.

The remuneration of each of the proposed Directors shall be determined with reference to his/her actual duties within the Group as recommended by the remuneration and appraisal committee of the Board ("**Remuneration and Appraisal Committee**") and after being approved by the Board. The proposed executive Directors who hold other positions in the Group will receive corresponding emoluments in accordance with the remuneration policy of the Company, which is determined with reference to their responsibilities, the operating results of the Company and the prevailing market conditions, but they will not receive remuneration for serving as Directors. The proposed non-executive Director shall receive a Director's fee of RMB100,000 per annum (exclusive of tax) from the Company as recommended by the Remuneration and Appraisal Committee and approved by the Board, upon the passing of the relevant resolution at the Annual General Meeting. Each of the proposed independent non-executive Directors will be entitled to a remuneration of RMB200,000 per annum (exclusive of tax) as recommended by the Remuneration and Appraisal Committee and approved by the Board, upon the passing of the relevant resolution at the Annual General Meeting.

Until the election of the new session of the Board has been completed, the members of the first session of the Board will continue to perform its duties in accordance with the relevant laws, regulations and the Articles of Association.

The resolutions regarding the election of the new session of the Board will be put forward for Shareholders' consideration and approval at the Annual General Meeting by ordinary resolution under a cumulative voting system.

III. POSTPONEMENT OF THE ANNUAL GENERAL MEETING

Reference is made to the Company's annual results announcement for the year ended December 31, 2025 (the "**Results Announcement**") dated March 31, 2026. As disclosed in the Results Announcement, the Annual General Meeting was originally scheduled to take place on Thursday, 18 June 2026. The Board hereby announces that, in view of the Company's current circumstances and in order to allow the Shareholders sufficient time to consider the resolutions, the Company has decided to postpone the Annual General Meeting, which was originally scheduled for Thursday, 18 June 2026, to Friday, 26 June 2026.

In order to determine the eligibility of the Company's H Share Shareholders to attend and vote at the Annual General Meeting, the register of members of H Shares will be closed from Tuesday, June 23, 2026 to Friday, June 26, 2026 (both days inclusive), during which period no transfers of H Shares will be made. In order to be eligible to attend and vote at the Annual General Meeting, all duly completed transfer forms accompanied by the relevant Share certificates must be lodged with the Company's H Share Registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not later than 4:30 p.m. on Monday, June 22, 2026, for registration.

Shareholders whose names appear on the Company's register of members on Friday, June 26, 2026 shall be entitled to attend and vote at the Annual General Meeting.

A circular containing, among other things, the details of the above resolutions, together with the notice of the Annual General Meeting and the related proxy form, will be dispatched to the Shareholders in due course in accordance with the relevant provisions of the Listing Rules and the Articles of Association.

By order of the Board
Vigonvita Life Sciences Co., Ltd.
Dr. Tian Guanghui
Chairman of the Board, Executive Director,
Chief Executive Officer and General Manager

Hong Kong, April 30, 2026

As at the date of this announcement, the Board comprises Dr. Tian Guanghui and Dr. Hu Tianwen as executive Directors, Mr. Liu Haoxuan as non-executive Director, and Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi as independent non-executive Directors.

APPENDICES: BIOGRAPHICAL DETAILS AND DISCLOSABLE INFORMATION REGARDING CANDIDATES FOR THE DIRECTORS

Candidates for executive Directors:

Dr. Tian Guanghui (田廣輝), aged 45, is the chairman of the Board, executive Director, chief executive officer and general manager of our Company. Dr. Tian joined our Company in January 2013 as a chief executive officer and has been a Director and the general manager of our Company since June 28, 2020 and the chairman of the Board since June 14, 2023. He was redesignated as the executive Director in January 2025. He has been the director and the general manager of Vigonvita Lianyungang since December 2019; the director of Yingjiu Health since December 2023 and the director of Qingdao Antai since April 2024. Dr. Tian is primarily responsible for the overall organizational management and operation of our Group. Dr. Tian has accumulated over 20 years of experience in the pharmaceutical industry. Prior to joining our Company, he worked as a manager at Yunnan Suwangrun Biopharmaceutical Co., Ltd. (雲南蘇旺潤生物醫藥有限公司) from September 2020 to September 2021. Dr. Tian served as a compositing director (合成總監) from August 2011 to December 2014 and worked as a laboratory manager from August 2007 to August 2008 at Topharman Shanghai, a pharmaceutical company specialized in R&D of active pharmaceutical ingredient. Dr. Tian also served as a supervisor in Shanghai Wangshi Biomedical Technology Co., Ltd. (上海旺實生物醫藥科技有限公司) from December 2021 to March 2023.

Dr. Tian obtained his master's degree and doctor's degree in medicinal chemistry from Shanghai Institute of Materia Medica of the CAS (中國科學院上海藥物研究所) in the PRC in July 2007 and July 2011, respectively. He obtained his qualification as a senior engineer from the Jiangsu Provincial Department of Human Resources and Social Security (江蘇省人力資源和社會保障廳) in August 2019.

As of the date of this announcement, Dr. Tian was interested in 14,316,611 shares of the Company, comprising 5,726,644 unlisted shares and 8,589,967 H shares.

Dr. Hu Tianwen (胡天文), aged 36, is the executive Director and deputy general manager of our Company. He was appointed as a Director in June 2023 and deputy general manager of our Company in March 2023. He was redesignated as an executive Director in January 2025. He has been appointed as the general manager of Vigonvita Shanghai since October 2022 and as a director of Vigonvita Lianyungang since June 2023. Dr. Hu is mainly responsible for the management and R&D strategy of our Group. Prior to joining our Group, Dr. Hu served as a researcher in Topharman Shanghai from July 2016 to September 2022.

Dr. Hu obtained his bachelor's degree in pharmaceutical engineering from Wannan Medical College (皖南醫學院) in the PRC in July 2012. He then obtained his master degree in pharmacy from Shanghai Institute of Materia Medica of the CAS (中國科學院上海藥物研究所) in the PRC in July 2016. He further achieved his doctor's degree in organic chemistry from Xinjiang Institute of Physics and Chemistry Technology of the CAS (中國科學院新疆理化技術研究所) in the PRC in June 2022.

As of the date of this announcement, Dr. Hu was interested in 681,743 H shares of the Company.

Candidates for non-executive Director:

Mr. Liu Haoxuan (劉浩軒), aged 51, is the non-executive Director of our Company. He was appointed as a Director in June 2020 and was redesignated as the non-executive Director in January 2025. He is mainly responsible for overseeing the management and operation of our Group. Mr. Liu currently serves as an executive director and general manager of Yunnan Suwangrun Biopharmaceutical Co., Ltd. (雲南蘇旺潤生物醫學有限公司), a company primarily engaged in pharmaceutical cosmetics production and wholesale, since September 2021. Mr. Liu served as an executive director of Yunnan Langrun Biotechnology Co., Ltd. (雲南莨潤生物科技有限公司), a company principally engaged in health products production and sale, from September 2020 to November 2024. Mr. Liu also served as a supervisor at Xiangcheng County Lingshan Tourism Co., Ltd. (襄城縣靈山旅遊有限公司), a company engaged in tourism services, from February 2019 to April 2023. He served as a supervisor at Suzhou AlphaMa Biotechnology Co., Ltd. (蘇州阿爾脈生物科技有限公司), a company principally engaged in biomedicine R&D, from July 2018 to November 2023, and has been serving as a chairman of the board and general manager since November 2023. From May 2021 to February 2022, he served as an executive director and general manager of Hainan Jiukuzhen Technology Development Co., Ltd. (海南九庫甄科技發展有限公司). From December 2019 to October 2020, he served as an executive director at Yunnan Shengtai Biotechnology Co., Ltd. (雲南升泰生物科技有限公司), a company primarily engaged in R&D in biotechnology.

Candidates for independent non-executive Directors:

Dr. Ju Dianwen (鞠佃文), aged 57, has been an independent director of our Company since March 27, 2023 and redesignated as independent non-executive Director of our Company since January 2025. He is mainly responsible for supervising the corporate governance of our Company and providing independent opinion to our Board. Dr. Ju has been a researcher of Department of Biomedicines, School of Pharmacy at Fudan University (復旦大學) in the PRC since 2011. Before that, Dr. Ju had successively served as a teaching assistant and lecturer in the Department of Medical Immunology at the Second Military Medical University (中國人民解放軍第二軍醫大學) then as a deputy general manager at Shanghai MediPharm Biotech Co., Ltd. (上海美恩生物技術有限公司), where he was responsible for the R&D in innovative drugs. Currently, Dr. Ju holds several positions in multiple companies, including (i) as a supervisor of Shanghai Dongci Biotechnology Co., Ltd. (上海東慈生物科技有限公司) since March 2019, (ii) as a scientific advisor of Novatim Immune Therapeutics (Zhejiang) Co., Ltd. (科弈(浙江)藥業科技有限公司) since October 2019, (iii) as a director of Xingshen Biotechnology (Hangzhou) Co., Ltd. (行深生物科技(杭州)有限公司) (previously known as Shanghai Xingshen Biotechnology Co., Ltd. (上海行深生物科技有限公司) since April 2020, (iv) as a director of Shanghai Xinze Venture Capital Management Co., Ltd. (上海莘澤創業投資管理股份有限公司) since December 2019, (v) as an independent non-executive director of Shanghai Bao Pharmaceuticals Co., Ltd. (上海寶濟藥業股份有限公司), a biotech company listed on the Main Board of the Stock Exchange (stock code: 2659), and (vi) as an independent director of Chengdu Olymvax Biopharmaceuticals Technology Co Ltd (成都歐林生物科技股份有限公司). From April 2020 to December 2024, Dr. Ju served as an independent director at Shanghai Baolong Pharmaceutical Co., Ltd. (上海寶龍藥業股份有限公司).

Dr. Ju obtained his bachelor's degree in pharmacy, master's degree in medicine, and doctor's degree in medical immunology from the Second Military Medical University (中國人民解放軍第二軍醫大學) in the PRC in July 1991, July 1994 and June 1999, respectively.

Ms. Cao Xinwen (曹新文), aged 48, has been an independent director of our Company since March 27, 2023 and redesignated as independent non-executive Director of our Company since January 2025. She is mainly responsible for supervising the corporate governance of our Company and providing independent opinion to our Board. Ms. Cao has accumulated more than 18 years of experience in accounting and management. Prior to joining our Company, Ms. Cao has been serving as a director of Jiangxi Tianyuan Environmental Protection Group Co., Ltd. (江西天沅環保集團股份有限公司), a company principally engaged in the R&D, production, and sales of fatty acid products from February 2018 to December 2024. She has been serving as the chief accountant of Shanghai Minxing Accounting Firm (上海民興會計師事務所) since February 2013 as well. Ms. Cao was an executive director of Jiangsu Huifang Enterprise Management Consulting Co., Ltd. (江蘇慧芳企業管理諮詢有限公司), a company principally engaged in business management consulting and software development, and she was responsible for project management from January 2018 to October 2019. She also served as an audit manager at Zhonglei Accounting Firm Shanghai Branch (中磊會計師事務所上海分所) from December 2006 to February 2008. She worked as an auditor at Shanghai Jianxin Bada Accounting Firm (上海建信八達會計師事務所) from May 2003 to November 2006. In addition, she served as an independent non-executive director at Zhejiang Jinsheng New Materials Co Ltd. (浙江錦盛新材料股份有限公司), an acrylic containers manufacturing company listed on the main board of the Shenzhen Stock Exchange (stock code: 300849) from November 2016 to November 2022.

Ms. Cao obtained her secondary vocational school diploma in financial accounting from Lianyungang Finance and Economics School (連雲港市財經學校) in the PRC in June 1996. She further obtained her bachelor's degree in management studies majoring in accounting from Nanjing University of Finance and Economics (南京財經大學) in the PRC in March 2005 through self studies. Ms. Cao was qualified for intermediate accounting (會計中級) from the Ministry of Finance (財政部) of the PRC in May 2002 and possesses Chinese Certified Public Accountant Certificate.

Dr. Xu Hongxi (徐宏喜), aged 64, has been the independent non-executive Director of our Company since January 2025. He is mainly responsible for supervising the corporate governance of our Company and providing independent opinion to our Board. Prior to joining our Company, Dr. Xu has been serving as a professor at the Shanghai University of Traditional Chinese Medicine (上海中醫藥大學) since December 2010. He was a deputy director at the Hong Kong Jockey Club Institute of Chinese Medicine (香港賽馬會中藥研究院) from October 2001 to November 2010. He served as a deputy general manager at Hutchison Whampoa (China) Limited (和記黃埔(中國)有限公司) from October 1999 to September 2001, and he was mainly responsible for the business related to Chinese medicines. He worked as a scientific officer at the Chinese Medicinal Material Research Centre of the Chinese University of Hong Kong (香港中文大學中藥研究中心) from September 1998 to September 1999. He served as a research associate at Dalhousie University in Canada from November 1996 to October 1997 and Department of Chemistry of National University of Singapore in Singapore from October 1994 to October 1996. In addition, he has been serving as (i) an independent non-executive director at Beijing Tong Ren Tang Chinese Medicine Company Limited (北京同仁堂國藥有限公司), a Chinese medicine manufacturing company listed on the Main Board of the Stock Exchange (stock code: 3613) since March 2023 and (ii) a non-executive director at JBM (Healthcare) Limited (健倍苗苗(保健)有限公司), a Hong Kong-based healthcare product marketing and distribution company listed on the Main Board of the Stock Exchange (stock code: 2161) since October 2025.

Dr. Xu obtained his bachelor's degree and master's degree in Chinese materia medica from the Shanghai University of Traditional Chinese Medicine (上海中醫藥大學) in the PRC in July 1983 and April 1989, respectively. Dr. Xu further obtained his Ph.D. degree in pharmaceutical science from the University of Toyama (日本富山醫科藥科大學) in Japan in March 1994. He received the title of "State Specially Recruited Experts" (國家特聘專家) from Organization Department of CCCPC (中共中央組織部) and Ministry of Human Resources and Social Security (人力資源和社會保障部).